Opinion|Videos|November 13, 2026

Choosing Between Regimens — and What’s Coming Next in the ADC Pipeline

Having this many therapeutic options for patients in this space is both exciting and a privilege.

Vue: That’s a good question. Having this many therapeutic options for patients in this space is both exciting and a privilege. One interesting feature of relacorilant is that although it is considered a targeted therapy, it does not require a biomarker for selection. Unlike mirvetuximab soravtansine, T-DXd, or immunotherapy — which depend on folate receptor alpha expression, HER2 expression, or PD-L1 status, respectively — relacorilant does not require a specific tumor biomarker to be active. When I’m selecting therapy, many of my decisions are biomarker driven. If a patient has an actionable target, I’ll often pursue that option. All of this is also layered against the patient’s side-effect profile. Patients in the platinum-resistant setting have typically been heavily pretreated and come to us with preexisting toxicities that can be debilitating and meaningfully affect quality of life. Those are the major considerations I weigh. What about you, Dr. Miller?

Miller: I think similarly. There are real quality-of-life considerations in treating these patients. As you said, by the time patients reach a platinum-resistant state they may be heavily pretreated and arrive with baseline toxicities. The KEYNOTE-B96 and ROSELLA regimens are both taxane based, so patients with baseline neuropathy may not be ideal candidates. Mirvetuximab soravtansine also carries some associated neuropathy. T-DXd is a strong option for patients with HER2-expressing disease, but as we know that is a minority of ovarian cancer patients, and patients with baseline pulmonary disease may not be the best candidates given the risk of pneumonitis.

Miller: I agree with you on biomarkers. Relacorilant from ROSELLA does not require a biomarker for eligibility — it is an all-comers option, which makes it a very tangible choice in clinic. It is also oral, dosed the day before, the day of, and the day after chemotherapy, which means much of the treatment is taken at home. KEYNOTE-B96 is FDA approved for patients with a PD-L1 combined positive score (CPS) of 1 or greater. Mirvetuximab soravtansine is FDA approved for patients with folate receptor alpha expression of 75% or greater, and T-DXd is limited to HER2-expressing disease. So I think all of these options are on the table, and the biomarker profile of the specific cancer and the baseline toxicities of the patient really drive the decision.

Vue: As I said earlier, it is a privilege to have this many treatment options in a disease that has historically been so challenging. Moving forward, I think this is the direction of future therapy — almost personalized medicine, where we can target specific tumors and spare patients from unnecessary toxicity.

Miller: We also have a lot of promising options still in development. We’ve now talked about two trials that have changed our standard of care, and those regimens are the new benchmark that any trial still in the pipeline will have to measure up against. There are a number of antibody–drug conjugates in development right now — we’ve seen phase 1 data for ADCs targeting CDH6, B7-H4, and additional folate receptor–directed constructs. Many have shown encouraging response rates and disease control rates in platinum-resistant ovarian cancer. So there is clear progress today, and genuinely exciting options still coming.

Vue: I couldn’t agree more. It’s an exciting time to be an oncologist, and we are making real strides in our therapy options for these patients.

Miller: I don’t think we’ve had this rate of progress in ovarian cancer in 40 to 50 years. It’s a very exciting time.

Vue: That’s the essence of communicating Between the Lines — taking the data and making it clear, honest, and useful. Thanks for watching this Between the Lines.


Related to this article